Keyphrases
Alzheimer's Disease
81%
Alzheimer's Disease Biomarkers
9%
Alzheimer's Disease Clinical Trials
17%
Alzheimer's Disease Prevention
10%
Amyloid Burden
10%
Autosomal Dominant Alzheimer's Disease
46%
Biomarker Changes
10%
Cerebrospinal Fluid
16%
Clinical Dementia Rating
12%
Clinical Outcomes
16%
Clinical Trials
49%
Cognitive Decline
10%
Cognitive Impairment
9%
Decline Rate
8%
Dementia
16%
DIAN-TU
11%
Disease Progression
25%
Disease Progression Modeling
9%
Disease Stage
9%
Disease-causing mutations
8%
Disease-modifying Therapy
11%
Dominantly Inherited Alzheimer Network
34%
Dominantly Inherited Alzheimer's Disease
67%
Early Alzheimer's Disease
9%
Gantenerumab
26%
Linear Mixed Model
12%
Longitudinal Change
17%
Longitudinal Data
9%
Mild Cognitive Impairment
9%
Mini-Mental State Examination
10%
Mixed Model Repeated Measures
12%
Multiple Sclerosis
14%
Mutation Carriers
29%
Neurodegeneration
9%
Non-carriers
17%
Pittsburgh Compound B
13%
Placebo
10%
Positron Emission Tomography
9%
Practice Effects
9%
Prevention Trials
11%
Progression Rate
8%
Rate of Change
26%
Sample Size Re-estimation
9%
Solanezumab
20%
Sporadic Alzheimer's Disease
20%
Standardized Uptake Value
15%
Symptom Onset
30%
Tau Pathology
9%
Total tau
10%
Treatment Effect
19%
Medicine and Dentistry
Alzheimer's Disease
100%
Alzheimer's Disease Clinical Trial
5%
Amyloid Plaque
7%
Amyloid Protein
42%
Amyloidosis
5%
Autosomal Dominant Inheritance
23%
Biological Marker
34%
Carbon 11
6%
Cerebrospinal Fluid
19%
Clinical Dementia Rating
7%
Clinical Trial
25%
Comorbidity
5%
Disease Exacerbation
8%
Diseases
12%
Gantenerumab
31%
Interim Analysis
5%
Mini-Mental State Examination
6%
Multiple Sclerosis
9%
Neurodegeneration
6%
Neuroinflammation
6%
Observational Study
9%
Pittsburgh Compound B
11%
Placebo
16%
Polyethylene Terephthalate
7%
Positron Emission Tomography
21%
Presenilin 1
9%
Prophylaxis
5%
Radioactive Tracer
9%
Solanezumab
20%
Standardized Uptake Value
9%
Tau
17%
Treatment Effect
5%
